NORP – Talk Bio

Roche Inks $80M Upfront Deal for Hansoh’s Cancer ADC HS-20110

1 week ago talkbio0Tagged CDH17 protein, human, Colorectal Carcinoma, Hansoh Pharmaceutical, HS-20110, milestone payments, Roche (company), royalties, Solid Neoplasm, therapeutic autologous dendritic cells, upfront payment

Roche; Hansoh Pharmaceutical; ADC; HS-20110; CDH17; colorectal cancer; solid tumors; licensing deal; upfront payment; milestone payments; royalties

Novo throws weight behind budding rare disease pipeline

1 week ago talkbio0Tagged complement system, MASP-3 Inhibitor, Novo Nordisk, Omeros, Paroxysmal nocturnal hemoglobinuria, Payments, pipeline, Rare Diseases, Zaltenibart

Novo Nordisk; rare disease; pipeline; Omeros; Zaltenibart; MASP-3 inhibitor; PNH; complement system; milestone payments

Spotlight On: Cabaletta Bio’s Small but Mighty Breakthrough for CAR-T in Autoimmune Arena

2 weeks ago talkbio0Tagged Autoimmune Diseases, B-Lymphocytes, Cabaletta Bio, CAR-T therapy, Clinical Trials, Depletion, Lupus Erythematosus, Systemic, Myositis, Pemphigus Vulgaris, Preconditioning, rese-cel, Systemic Scleroderma, United States Food and Drug Administration

Cabaletta Bio; CAR-T therapy; rese-cel; autoimmune diseases; B cell depletion; myositis; systemic lupus erythematosus; systemic sclerosis; pemphigus vulgaris; preconditioning; clinical trial; FDA

AnaptysBio Announces Strategic Business Split to Create Two Public Companies, Sharpening Asset Focus

4 weeks ago talkbio0Tagged AnaptysBio, asset, biopharmaceutical development, business split, Immunology, Imsidolimab, Jemperli, public companies, restructuring, royalty management

AnaptysBio; business split; royalty management; biopharmaceutical development; Jemperli; imsidolimab; public companies; immunology treatments; asset value; restructuring

Servier Supercharges Neuro Pipeline with $450M Deal for Fragile X Syndrome Candidate

2 months ago talkbio0Tagged Acquisition, Bioscience, deal, Fragile X Syndrome, Infrequent, Kaerus, KER-0193, orphan drug designation, pediatric drug designation, Phase 2 trial, Servier

Servier; Kaerus Bioscience; KER-0193; Fragile X syndrome; neurology pipeline; $450 million deal; orphan drug designation; rare pediatric drug designation; Phase 2 trial; acquisition

MRM Health Nets $64M and Treeline Gathers $200M: Fierce Biotech Fundraising Tracker 2025

2 months ago talkbio0Tagged Biocodex, Biotech Fundraising, Inflammatory Bowel Diseases, LBP, Live Biotherapeutic Product, Microbiome therapeutics, MRM Health, Series B funding, Treeline, Ulcerative Colitis

MRM Health; Series B Funding; Microbiome therapeutics; Ulcerative colitis; Live Biotherapeutic Product (LBP); Biocodex; Treeline; Biotech fundraising; IBD therapy

Treeline Announces $200M Funding Boost, Moves Three Cancer Drugs into Clinic

2 months ago talkbio0Tagged BCL6 gene, cancer drugs, Clinical Trials, Degrader, EZH2 protein, human, Funding, Inhibitor, K-ras Oncogene, Lymphoma, Series, Solid Neoplasm, TLN-121, TLN-254, TLN-372, Treeline

Treeline Biosciences; cancer drugs; clinical trials; TLN-121; TLN-372; TLN-254; BCL6 degrader; KRAS inhibitor; EZH2 inhibitor; Series A funding; lymphoma; solid tumors

Royalty Pharma Buys $885M Imdelltra Royalty Stake from BeOne

2 months ago talkbio0Tagged amgen, bispecific, DLL3, DLL3 gene, ES-SCLC, Imdelltra, Malignant neoplasm of lung, Royalty, Small cell carcinoma of lung, upfront

BeOne Medicines; Imdelltra; Amgen; Royalty Pharma; $885 million upfront; lung cancer; royalty deal; DLL3 bispecific; small cell lung cancer; ES-SCLC

Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program

3 months ago talkbio0Tagged Chinese biotech, Clinical Development, Inhibitor, Janus kinase, Minghui, Neoplasms, PD-1xVEGF bispecific, pre-IPO ', therapeutic autologous dendritic cells, trials

Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development

Pfizer, Astellas’ Xtandi Combo Extends Survival in Early Prostate Cancer

4 months ago talkbio0Tagged Astellas, BCR, biochemical recurrence, Combined Modality Therapy, EMBARK, enzalutamide, leuprolide, Malignant neoplasm of prostate, nmHSPC, non-metastatic, Overall Survival, Pfizer, Xtandi

Pfizer; Astellas; Xtandi; Enzalutamide; prostate cancer; overall survival; combination therapy; leuprolide; non-metastatic hormone-sensitive prostate cancer (nmHSPC); EMBARK study; biochemical recurrence (BCR)